E1 ReplicatedPreliminaryPEM requiredRCTPeer-reviewedMachine draft
Impact of combined plant extracts on long COVID: An exploratory randomized controlled trial.
Lukkunaprasit, Thitiya, Satapornpong, Patompong, Kulchanawichien, Pongsiri et al. · Complementary therapies in medicine · 2024 · DOI
Quick Summary
Researchers tested whether a supplement made from five plant extracts could help people with long COVID feel better. Over 7 days, people taking the supplement reported feeling less fatigued and had fewer severe symptoms like post-exertional malaise (worsening after activity) compared to those taking a placebo. The supplement was generally safe, though the study was small and longer research is needed to confirm these results.
Why It Matters
Long COVID shares clinical features with ME/CFS, particularly post-exertional malaise and fatigue. This study offers preliminary evidence that plant-based interventions may reduce symptom burden in post-viral conditions, though validation in larger trials is critical for establishing clinical utility and understanding mechanisms relevant to ME/CFS pathophysiology.
Observed Findings
- Combined plant extract reduced total symptom score by median 4 points compared to placebo (95% CI -7.58 to -0.42).
- Relative risk of moderate-to-severe fatigue was 0.25 in the CPE group versus placebo (95% CI 0.08–0.81).
- Relative risk of moderate-to-severe post-exertional malaise was 0.35 in the CPE group versus placebo (95% CI 0.16–0.78).
- C-reactive protein levels did not differ significantly between groups (MD -0.05 mg/L, 95% CI -0.49–0.39).
- Adverse events were mild and resolved by end of follow-up.
Inferred Conclusions
- Combined plant extract may alleviate moderate-to-severe long COVID symptoms, particularly fatigue and post-exertional malaise, with an acceptable safety profile.
- Inflammatory markers (CRP) may not be the primary mechanism by which the supplement produces symptomatic benefit.
- Larger-scale, longer-duration trials are necessary to validate these preliminary findings and establish clinical significance.
Remaining Questions
- What is the durability of symptom improvement beyond the 7-day intervention period, and do benefits persist or reverse after treatment cessation?
- Which specific plant components (or combinations thereof) drive the observed reductions in fatigue and post-exertional malaise?
What This Study Does Not Prove
This study does not establish that the supplement is effective for ME/CFS, only for a long COVID cohort over 7 days. The short duration prevents assessment of sustained benefit or relapse rates. The unvalidated symptom questionnaire raises questions about whether the reported improvements reflect true clinical benefit or measurement artifact, and the lack of CRP reduction suggests the mechanism of symptom improvement remains unclear.
Tags
Symptom:Post-Exertional MalaiseFatigue
Biomarker:Blood Biomarker
Phenotype:Long COVID Overlap
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
Metadata
- DOI
- 10.1016/j.ctim.2024.103107
- PMID
- 39488240
- Review status
- Machine draft
- Evidence level
- Replicated human evidence from multiple independent studies
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →